Literature DB >> 7859389

Protective role of bradykinin in cardiac anaphylaxis. Coronary-vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms.

L E Rubin1, R Levi.   

Abstract

Cardiac anaphylaxis, an acute ischemic dysfunction comprising coronary vasoconstriction and arrhythmias, is a model of clinically recognized immediate hypersensitivity reactions affecting the heart. Bradykinin, a mediator of hypersensitivity, is also a potent coronary vasodilator, acting via nitric oxide and prostacyclin production. Because ischemia increases bradykinin outflow from the heart, we questioned whether bradykinin might mitigate anaphylactic coronary vasoconstriction. Antigen challenge of hearts isolated from presensitized guinea pigs was associated with an approximately 30% increase in bradykinin overflow. Furthermore, (1) when the half-life of bradykinin was prolonged with the kininase II/angiotensin-converting enzyme inhibitors captopril and enalaprilat, anaphylactic coronary vasoconstriction was attenuated and reversed, and arrhythmias were alleviated; (2) the bradykinin B2-receptor antagonist HOE 140 prevented these effects; and (3) HOE 140 exacerbated both anaphylactic coronary vasoconstriction and arrhythmias. During cardiac anaphylaxis, the coronary overflow of cGMP, a marker of nitric oxide production, and 6-ketoprostaglandin F1 alpha, a stable prostacyclin metabolite, increased two-fold and fourfold, respectively. Because neither enalaprilat nor HOE 140 affected these changes, the enhanced overflow of cGMP and 6-ketoprostaglandin F1 alpha is likely to reflect the actions of other hypersensitivity mediators (eg, histamine and leukotrienes). We postulate that bradykinin plays a protective role in cardiac anaphylaxis by accumulating at the luminal surface of the coronary endothelium and promoting, in an autocrine mode, a B2-receptor-mediated production of nitric oxide and prostacyclin in concentrations sufficient to elicit a paracrine effect on coronary vascular smooth muscle, thus opposing the vasoconstricting effects of other anaphylactic mediators.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7859389     DOI: 10.1161/01.res.76.3.434

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response.

Authors:  A Clerk; J Gillespie-Brown; S J Fuller; P H Sugden
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

2.  A kallidin-like peptide is a protective cardiac kinin, released by ischaemic preconditioning of rat heart.

Authors:  Xiuxin Liu; Martina Lukasova; Radka Zubakova; Sabina Lewicka; Ulrich Hilgenfeldt
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 3.  The kinin system in hypertensive pathophysiology.

Authors:  Jagdish N Sharma
Journal:  Inflammopharmacology       Date:  2012-04-17       Impact factor: 4.473

4.  Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis.

Authors:  Wei-Qing Rang; Yan-Hua Du; Chang-Ping Hu; Feng Ye; Gui-Shan Tan; Han-Wu Deng; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-04       Impact factor: 3.000

Review 5.  Role of nitric oxide in anaphylactic shock.

Authors:  H Mitsuhata; R Shimizu; M M Yokoyama
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

Review 6.  The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Authors:  Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 7.  Pathophysiological, Cellular, and Molecular Events of the Vascular System in Anaphylaxis.

Authors:  Emilio Nuñez-Borque; Sergio Fernandez-Bravo; Alma Yuste-Montalvo; Vanesa Esteban
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.